C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.

Shattuck Labs Reveals Promising Early Results from Continual Phase 1 A/B Clinical Study of SL-172154 Combined with Azacitidine in Newly Diagnosed Advanced Myelodysplastic Conditions (HR-MDS) and TP53 Mutation-Positive Acute Myeloid Leukemia Patients.

Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.

The European Commission has sanctioned Blueprint Medicines' drug AYVAKYT® (avapritinib) as the exclusive therapeutic option for indolent systemic mastocytosis.

Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).

The FDA is reviewing the updated New Drug Application (NDA) for TransCon PTH (also known as Palopegteriparatide) meant for the treatment of hypoparathyroidism in adults.

Vertex Pharmaceuticals Incorporated declared favorable outcomes from its Phase 2 trial assessing various dosages of the targeted NaV1.8 inhibitor, VX-548, in individuals suffering from painful diabetic peripheral neuropathy.

Wugen Unveils Initial Results from Early-Stage Clinical Assessment of WU-CART-007 in Hard-to-Combat Hematologic Malignancies at the Yearly American Hematology Conference.

Connect Biopharma has revealed encouraging primary outcomes from its global Phase 2b trial of Rademikibart in treating adults with moderate to severe chronic asthma.

GigaGen Inc. has announced FDA approval for its IND application. This permits the start of a Phase 1 trial to evaluate GIGA-564's effectiveness in treating diverse solid cancers.

Biotech company UNITY Biotechnology has launched its Phase 2 ASPIRE trial, administering its aging-focused drug UBX1325 (foselutoclax) to the first patients.

Mabwell announced its Phase III trial application for 9MW2821 vs. standard chemo in advanced urothelial carcinoma.